Investors Mull Reciprocal Tariffs, Asia Mixed
Asia-Pacific markets were mixed Friday, after Wall Street rose overnight as President Donald Trump signed a reciprocal tariffs plan, but did not enact the levies immediately.In Japan, the Nikkei 225 index dumped 312.04 points, or 0.8%, to 39,149.43. In Hong Kong, the Hang Seng index took off like a Saturn rocket, catapulted 805.96 points, or 3.7%, to 22,629.33. The index is on track to its highest weekly gain since October.Korean markets made slight gains, as the country’s seasonally adjusted unemployment rate hit 2.9% in January, easing from its three-year high of 3.7% in the month before.In Southeast Asia, Singapore’s economy expanded by 4.4% in 2024, its fastest growth since 2021, data from the Ministry of Trade and Industry shows. GDP was up 5% year on year in the fourth-quarter of 2024, surpassing the 4.7% growth rate expected by Reuters.Investors have been watching the city-state’s Straits Times Index which hit an all-time high at the start of the week. In other marketsThe CSI 300 in mainland China recovered 33.87, or 0.9% to 3,939.01In Taiwan, the Taiex index shed 246.80 points, or 1.1%, to 23,152.61.In Singapore, the Straits Times index lost 5.08 points, or 0.1%, to 3,877.50In Korea, the Kospi index notched higher 7.88 points, or 0.3%, to 2,591.05.In New Zealand, the NZX 50 sprang back up 83.2 points, or 0.6%, to 12,989.18In Australia, the ASX 200 gained 15.85 points, or 0.2%, to 8,555.81.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


